Press release
Irritable Bowel Syndrome Treatment Market is Growing at 8.7% CAGR to Surpass US$ 9,355.4 Million by 2034: Fact.MR Report
Irritable Bowel Syndrome Treatment Market
The market for treatments for irritable bowel syndrome is predicted to grow at a compound annual growth rate (CAGR) of 8.7% between 2024 and 2034, based on Fact.MR's study of market trends. By the end of 2034, the industry's net valuation is predicted to reach a whopping US$ 9,355.4 million if this profitable growth rate continues.
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ ๐จ๐ ๐๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ: https://www.factmr.com/connectus/sample?flag=S&rep_id=9520
The industry's present and upcoming technical and financial facts are accessible in the Irritable Bowel Syndrome Treatment Market 2024 Report. It is among the most extensive and significant additions to the library of market research studies from Prudent Markets. It provides thorough investigation and evaluation of the major facets of the worldwide market for treatments for irritable bowel syndrome. This study examines every significant aspect influencing the expansion of the worldwide market for treatments for irritable bowel syndrome, including the demand-supply situation, pricing strategies, profit margins, production, and value chain analysis.
๐๐๐ ๐ข๐จ๐ง๐๐ฅ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐๐จ๐ซ ๐๐ซ๐ซ๐ข๐ญ๐๐๐ฅ๐ ๐๐จ๐ฐ๐๐ฅ ๐๐ฒ๐ง๐๐ซ๐จ๐ฆ๐ ๐๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐๐๐ซ๐ค๐๐ญ:
North America (the USA and Canada)
Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
Latin America(Brazil, Mexico and Rest of Latin America)
Middle East & Africa(South Africa, GCC and Rest of the Middle East & Africa)
๐๐จ๐ฆ๐ฉ๐๐ญ๐ข๐ญ๐ข๐ฏ๐ ๐๐๐ง๐๐ฌ๐๐๐ฉ๐
The emergence of players concentrating on other healthcare services earlier has made the global network of suppliers of irritable bowel syndrome treatment services more competitive. Due to the rising need for IBS patients' healthcare, small-scale market participants have gained prominence recently, especially in emerging economies.
Recent Developments by Irritable Bowel Syndrome Treatment Industry Participants
To raise awareness among patients with gastrointestinal diseases, Abbott Laboratories and the Nutrition Society of India collaborated to give clinical dietary recommendations specifically customized for the Indian market in March 2021. GI conditions such as functional constipation, peptic ulcers, chronic pancreatitis, and irritable bowel syndrome are anticipated to generate sufficient economic possibilities for Abbott in the nation.
Ferring B.V., a biopharmaceutical business, announced in June 2022 that it has teamed with I-MAB Biopharma Limited, a well-known biopharma company with an emphasis on innovation. Olamkicept is a selective interleukin-6 (IL-6) trans-signaling inhibitor that is being developed by the two businesses to treat inflammatory bowel disease (IBD) and related inflammatory diseases.
๐๐๐ญ ๐๐ฎ๐ฌ๐ญ๐จ๐ฆ๐ข๐ณ๐๐ญ๐ข๐จ๐ง ๐จ๐ง ๐ญ๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐จ๐ซ ๐๐ฉ๐๐๐ข๐๐ข๐ ๐๐๐ฌ๐๐๐ซ๐๐ก ๐๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง๐ฌ: https://www.factmr.com/connectus/sample?flag=RC&rep_id=9520
๐๐๐ฒ ๐๐๐ ๐ฆ๐๐ง๐ญ๐ฌ ๐๐จ๐ฏ๐๐ซ๐๐ ๐๐ฒ ๐๐ซ๐ซ๐ข๐ญ๐๐๐ฅ๐ ๐๐จ๐ฐ๐๐ฅ ๐๐ฒ๐ง๐๐ซ๐จ๐ฆ๐ ๐๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐๐ฎ๐ซ๐ฏ๐๐ฒ ๐๐๐ฉ๐จ๐ซ๐ญ
By Poduct Type:
Fiber Supplements
Anti-Diarrheal
Anticholinergic and Antispasmodic
Antidepressant
Antibiotics
Alosetron
Lubiprostone
Linaclotide
NHE3
By Indication:
Irritable Bowel Syndrome with Constipation
Irritable Bowel Syndrome with Diarrhea
Irritable Bowel Syndrome with Alternating Constipation and Diarrhea
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies and Stores
Hypermarkets and Supermarkets
Other Distribution Channels
By Region:
North America
Europe
Latin America
East Asia
South Asia & Oceania
The Middle East & Africa (MEA)
๐๐จ๐ง๐ญ๐๐๐ญ:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com
๐๐๐จ๐ฎ๐ญ ๐ ๐๐๐ญ.๐๐
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Irritable Bowel Syndrome Treatment Market is Growing at 8.7% CAGR to Surpass US$ 9,355.4 Million by 2034: Fact.MR Report here
News-ID: 3482218 • Views: โฆ
More Releases from Fact.MR
USA Demand for Microbiome Skincare Products in USA Outlook 2025-2035: Key Develo โฆ
The U.S. microbiome skincare market is projected to experience rapid, data-driven growth over the next decade, driven by rising consumer awareness, ingredient innovation, and the integration of personalized diagnostics. Analysts estimate the U.S. microbiome skincare segment at approximately USD 0.13 billion in 2025, with a projected increase to USD 0.35 billion by 2035, representing a compound annual growth rate (CAGR) of 10.4%.
To access the complete data tables and in-depth insights,โฆ
USA Demand for Lubricants in USA Outlook 2025-2035: Key Developments and Future โฆ
The U.S. lubricants market is projected to experience steady growth through 2035, driven by shifts in mobility, industrial demand, and sustainability trends. The market was valued at approximately $41.2 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 2.5%, reaching $52 billion by 2035.
To access the complete data tables and in-depth insights, request a Discount On The Report here: https://www.factmr.com/connectus/sample?flag=S&rep_id=12463
โฆ
European Demand for Intermodal Freight Transportation in UK Outlook 2025-2035: K โฆ
"Demand for intermodal freight transport connecting the UK and continental Europe is projected to grow at a CAGR of 6.8% between 2025 and 2035, driven by rising trade volumes, decarbonization mandates, and digital logistics innovations. The intermodal market, encompassing rail, short-sea shipping, and last-mile road delivery, is expected to handle over 18 million TEUs (twenty-foot equivalent units) annually by 2035, up from 10.2 million TEUs in 2025.
To access the completeโฆ
USA Demand for Hydroxyapatite in USA Outlook 2025-2035: Key Developments and Fut โฆ
The United States hydroxyapatite (HAp) market is projected to experience sustained, data-driven growth from 2025 through 2035, fueled by rising clinical demand, technological innovation, and expanded applications in regenerative medicine. Market modeling indicates that U.S. consumption of hydroxyapatite will nearly double over the next decade, with strong adoption in orthopedic, dental, and advanced biomaterial sectors.
To access the complete data tables and in-depth insights, request a Discount On The Report here:โฆ
More Releases for Irritable
Irritable Bowel Syndrome Medication Market Massive Growth opportunity Ahead
Exactitude Consultancy., Ltd. announces the release of the report "Global Irritable Bowel Syndrome Medication Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets.โฆ
Irritable Bowel Syndrome Treatment Market | $2 Billion by 2026
The market for treating irritable bowel syndrome (IBS) has witnessed significant growth in recent years. In 2018, the estimated value of the IBS treatment market was $1,071 million. However, with increasing awareness and advancements in medical research, the market is projected to reach a staggering $2,012 million by 2026. This represents a remarkable compound annual growth rate (CAGR) of 8.2% during the forecast period from 2019 to 2026.
Irritable bowel syndromeโฆ
Irritable Bowel Syndrome Treatment Market - Industry Trends and Forecast to 2028
The Global Irritable Bowel Syndrome Treatment Market Growth at a rate of 9.32% in the forecast period 2022 to 2028
Global Irritable Bowel Syndrome Treatment Market Size
Irritable bowel syndrome treatment market is segmented on the basis of type, product and end use. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help themโฆ
Global Irritable Bowel Syndrome Treatment Market Strategical Analysis Report 202 โฆ
The primary purpose of the statistical analysis is to use data analysis and descriptive statistics. It helps to summarize data from a sample using indexes like mean or standard deviation and inferential statistics. This report includes information and statistics on price levels, location of the product, and demand for the product. The best thing about the statistical analysis report is that it allows businesses to make decisions in terms ofโฆ
Irritable Bowel Syndrome (IBS) Treatment Market: Increasing Prevalence of Irrita โฆ
The major factors such as the increasing prevalence of irritable bowel syndrome diseases and rising research & development activities drive the market growth. However, the limited number of product availability and treatment inefficiency restrain the market growth. IBS is a common chronic condition that affects the abdominal organ, large intestine. It is also known as spastic colon, mucous colitis, irritable colon, and spastic colitis. The condition is much different thanโฆ
Ayurvedic Cure For Irritable Bowel Syndrome (IBS) Without Operation
The Grocare is a leading natural solution provider for chronic lifestyle diseases โ Irritable bowel syndrome (IBS), is a gift of enterprise, and commitment to quality and modern-day buyersโ changing needs. Grocare conforms to stringent quality-related compliances and cost-efficient processes in all aspects of formulation and production. At Grocare, we use natural ingredients developed over the years of research and development. It is FDA certified, safe to use, and affordableโฆ
